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Introduction: MET proto-oncogene, receptor tyrosine
kinase gene exon 14 skipping (METex14) alterations
represent a unique subset of oncogenic drivers in NSCLC.
Preliminary clinical activity of crizotinib against METex14-
positive NSCLC has been reported. The full spectrum of
resistance mechanisms to crizotinib in METex14-positive
NSCLC remains to be identiﬁed.
Methods: Hybrid capture–based comprehensive genomic
proﬁling performed on a tumor specimen obtained
at diagnosis, and a hybrid capture–based assay of
circulating tumor DNA (ctDNA) at the time of progression
during crizotinib treatment was assessed in a pairwise
fashion.
Results: A METex14 alteration (D1010H) was detected in
the pretreatment tumor biopsy specimen, as was MET
proto-oncogene, receptor tyrosine kinase (MET) Y1230C,
retrospectively, at very low frequency (0.3%). After a
conﬁrmed response during crizotinib treatment for 13
months followed by progression, both MET proto-oncogene,
receptor tyrosine kinase gene Y1230C and D1010H were
detected prospectively in the ctDNA.
Conclusion: Emergence of the preexisting MET Y1230C
likely confers resistance to crizotinib in this case of
METex14-positive NSCLC. Existence of pretreatment
MET Y1230C may eventually modulate the response
of METex14-positive NSCLC to type I MET tyrosine
kinase inhibitors. Noninvasive plasma-based ctDNA
assays can provide a convenient method to detect resis-
tance mutations in patients with previously known driver
mutations. 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
MET proto-oncogene, receptor tyrosine kinase gene
(MET) exon 14 skipping (METex14) alterations are now
recognized as important driver mutations in NSCLC.1
Crizotinib, a MET proto-oncogene, receptor tyrosine
kinase (MET) tyrosine kinase inhibitor (TKI), has
demonstrated activity against NSCLC with METex14
alterations.2 As with the use of targeted therapy in
other oncogene-driven tumors, speciﬁc mechanisms ofJournal of Thoracic Oncology Vol. 12 No. 1: 137-140
138 Ou et al Journal of Thoracic Oncology Vol. 12 No. 1acquired resistance to MET TKI are anticipated and have
been recently described.3 Structural insights from the
binding interaction of crizotinib in the MET kinase
domain suggest that certain amino acid changes may
confer broader resistance to other type I MET TKIs.4 It is
important to identify the mechanisms of resistance to
crizotinib in METex14-positive NSCLC to help guide
subsequent therapy with structurally divergent in-
hibitors. However, repeat tumor biopsy at progression
can be difﬁcult. The availability of a noninvasive plasma-
based assay provides an alternate method to assess
resistance. Here, by using a plasma-based circulating
tumor DNA (ctDNA) assay, we have identiﬁed a clinically
novel MET mutation after progression during crizotinib
treatment in a patient with METex14-positive NSCLC
after a conﬁrmed durable response.
Methods
Patients withMETex14-positive NSCLC as identiﬁed by
comprehensive genomic proﬁling (CGP) of tissue speci-
mens5 were enrolled into theMETex14-positive expansion
cohort of the phase 1 crizotinib trial (ClinicalTrials.gov
identiﬁer NCT00585195). For this case, at time
of progression, a ctDNA assay (FoundationACT [Founda-
tion Medicine, Inc., Cambridge, MA]) was performed
to assess potential resistance mechanisms and inform
therapy for the patient after cessation of treatment on
the clinical trial. Speciﬁcally, the Clinical Laboratory
Improvement Amendments–validated FoundationACT
assay was conducted as follows. Two 10-mL aliquots
of peripheral whole blood were collected in cell-free
DNA blood collection tubes. A double-spin protocol was
used to isolate plasma, and 50 to 100 ng of ctDNA was
extracted to create adapted sequencing libraries before
hybrid capture and sample-multiplexed sequencing
on an Illumina HiSeq 2500 sequencer (Illumina, San
Diego, CA). The FoundationACT ctDNA test covers 62Figure 1. Computed tomography scans of the patient before c
progression during crizotinib treatment.genes to 5000 unique coverage and uses proprietary al-
gorithms to call alterations at low allele frequencies (0.1%
for substitutions, 1% for indels and rearrangements, and
20% for copy number ampliﬁcations). Mutant allele
frequency (MAF) for the tissue-based assay represents
the percentage of DNA obtained from the mutation-
containing tumor on which a biopsy was performed.
In the blood, MAF represents the percentage of ctDNA
in the bloodstream that is harboring the mutation on a
given day and time. For this reason, MAF for
the tissue assay and ctDNA assays cannot be directly
compared.
Results
Stage IV metastatic adenocarcinoma of the lung was
diagnosed in a 67-year-old Asian female never-smoker
when she presented with superior vena caval syn-
drome and a 7-pound weight loss. Imaging studies
revealed large right hilar and subcarinal lymphadenop-
athy with compression of the right mainstem bronchus,
moderate right pleural effusion, and a right lower lung
mass (Fig. 1) and brain metastasis. Endobronchial
ultrasound–guided biopsy of the mediastinal lymph
nodes revealed poorly differentiated adenocarcinoma
(CK7 positive, TTF-1–positive, CK20 negative). The
patient received stereotactic radiosurgery to the brain
and one cycle of carboplatin/paclitaxel. CGP of the initial
tissue specimen from the biopsy performed as part of
standard of care revealed a METex14 alteration (MET
D1010H) (44% MAF) but no concurrent MET ampliﬁca-
tion. Of note, retrospective analysis of the original CGP
testing revealed that two of 762 sequencing reads
(0.26%) showed the Y1230C mutation present at well
below reportable levels of the assay (Fig. 2 [upper panel]).
She was enrolled onto a phase 2 trial of crizotinib in pa-
tients with METex14-positive NSCLC (ClinicalTrials.gov
Identiﬁer NCT00585195). She achieved a conﬁrmedrizotinib treatment, conﬁrmed response to crizotinib, and at
Figure 2. Comprehensive genomic proﬁling proﬁling of a pre–crizotinib treatment tumor tissue sample showing MNNG HOS
Transforming gene (MET) exon 14 skipping alteration (D1010H) and the presence of Y1230C mutation (red circle) at a very low
frequency (upper panel). Circulating tumor DNA assay detecting the presence of the original METexon 14 skipping alteration
and the Y1230C resistance mutation, both at reportable levels (lower panel). Percentages indicate the mutant allele fre-
quency for the given assay.
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(see Fig. 1) and maintained a PR for nearly 13 months, at
which point metastasis to her right cervical lymph nodes
developed. Restaging of the patient revealed progression
of her brain metastases (see Fig. 2). Because of ongoing
response in the right hilar mass and the vascular cervical
metastasis, a tissue sample could not be safely obtained. A
ctDNA assay was performed; it conﬁrmed the presence of
the previously detected primary METex14 (D1010H)
alteration at 10.9% MAF and also detected the
MET Y1230C resistance mutation at a MAF of 3.5% (see
Fig. 2 [lower panel]). The patient received whole brain
radiation and radiation to the right side of the neck
but declined further chemotherapy or an alternate MET
TKI and returned to her native country.
Discussion
This is the ﬁrst clinical report that Y1230C mutation
occurs in METex14-positive NSCLC after progression
during crizotinib treatment. The MET receptor tyrosine
kinase adopts a unique inactive conformation, with the
activation loop spanning the adenosine triphosphate
binding site through several critical interactions,
including the salt pair involving an aspartate residue at
1228 (D1228) with a lysine residue at 1110 (K1110)
that stabilizes the position of the tyrosine residue at
1230 (Y1230).4 Y1230 lies in the activation loop and is
locked inside the adenosine triphosphate binding area
through interaction with A1226. Type I MET TKIs such
as crizotinib bind to the MET unique autoinhibitory
conformation through interaction of the aromatic ring
of the inhibitor (p stacking) with Y1230 in the METactivation loop.4 Substitution of tyrosine with a cysteine
abolishes this interaction and weakens the binding af-
ﬁnity of crizotinib and other type I inhibitors with the
MET kinase domain.4 In vitro mutagenesis experiments
have indicated that mutations at Y1230 and D1228 are
the two most common types of acquired mutations
identiﬁed in the setting of type I MET TKI resistance,
including resistance to crizotinib.5,6 A D1228N acquired
resistance mutation to crizotinib in METex14-positive
NSCLC has recently been reported clinically.3 Thus,
mutations at Y1230 and D1228 are likely to be the
Achilles’ Heel for all type I MET TKIs. Indeed, another
type I MET TKI, AMG337, is ineffective against Y1230
and D1228 mutations.7 On the other hand, merestinib, a
type II MET TKI, is less dependent on the p stacking
interaction with Y1230 given its additional interaction
with the hydrophobic back pocket of the MET kinase
domain, and it has inhibitory activity against wild-type
MET similar to that against MET Y1230C.8 Currently,
several clinical trials involving type I MET TKIs
such as crizotinib (NCT00585195, NCT02465060
[NCI-MATCH], and NCT02499614 [METROS]) capmati-
nib (NCT02750215), and tepotinib (NCT02864992) and
type II inhibitors such as cabozatinib (NCT01639508)
and glesatinib (NCT02544633) in METex14-positive
NSCLC are ongoing. CGP of tissue or assay of ctDNA
at time of disease progression will likely help guide
optimal treatment with the two major classes of MET
TKIs on the basis of the resistance mechanisms detected.
Importantly, in this report Y1230C was already
detectable at a very low frequency at the time of diag-
nosis before any treatment, when it was looked for
140 Ou et al Journal of Thoracic Oncology Vol. 12 No. 1retrospectively. The preexistence of low-level MET
Y1230C before treatment is novel and similar to the low
level of EGFR T790M mutation or MET ampliﬁcation
observed in patients with treatment-naive EGFR-
mutated NSCLC.9,11 The existence of the T790M
mutation negatively modulated the response and
progression-free survival of EGFR-positive patients to
ﬁrst-generation EGFR TKIs.9 Our patient did achieve a
conﬁrmed PR to crizotinib for 13 months before pro-
gressing, indicating that the low level of Y1230C did not
confer upfront resistance but likely did play a role in the
disease progression. The prospective detection of MET
Y1230C as an acquired resistance mechanism to a type I
MET TKI in a patient with METex14-positive NSCLC us-
ing a clinically validated assay points to the importance
of developing type II MET TKIs and/or utilizing total
blockade of the MET axis with neutralizing antibodies
to the MET receptor or its ligand.10 Although the MAF
of Y1230C in pretreatment tissue cannot be directly
compared with the MAF as detected in the posttreatment
blood sample, given the enrichment of Y1230C relative
to the D1010H primary mutation in the posttreatment
sample as well as the structural and preclinical data
indicating that Y1230C is a resistance mechanism, given
the clinical context, the emergence of Y1230C likely
contributed to disease progression in our patient.
Patients with METex14-positive NSCLC are gener-
ally elderly, and the incidence of brain metastasis at
the time of diagnosis, and more importantly at the time
of progression during treatment with a MET TKI, re-
mains to be determined.12 Crizotinib has limited cen-
tral nervous system (CNS) penetration.13 Thus,
whether CNS progression in our patient was due to
limited penetration of crizotinib and/or the Y1230C
mutation is unknown. For patients with METex14-
positive NSCLC with CNS progression during crizoti-
nib treatment, the practical utility of a convenient
ctDNA assay to detect the presence or absence of
known or predicted resistance mutations may direct
future therapy toward type II MET TKIs with CNS ac-
tivity such as cabozantinib14 or to type I MET TKIs with
better CNS activity, respectively. Limitations to the
plasma-based detection method include the inability
to detect histologic changes such as epithelial-
mesenchymal transition15 small cell transformation16
or potential upregulation of the MET ligand.10 None-
theless, given the speciﬁc binding interactions of type I
MET TKIs in the MET kinase domain, enrichment of
preexisting resistance mutations or development of
acquired ones such as Y1230 or D1228 will likely be
the prevailing mode of resistance, and plasma-based
ctDNA assays will provide a noninvasive method to
detect these likely dominant resistance mutations to
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